Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Barr Premarin Petition On Misleading Labeling May Be Renewed; ANDA Planned

  • News

Executive Summary

Barr will decide by the end of January whether to continue to pursue its citizen petition claiming that labeling for Wyeth-Ayerst's Premarin (conjugated estrogens) is false and misleading

You may also be interested in...



Wyeth Premarin Petition Withdrawn; Firm Hints At Future Action

Wyeth is reserving its right to file future citizen petitions with regard to the manufacturing of generic Premarin (conjugated estrogens), the company says in a letter formally withdrawing a 1994 petition to block synthetically derived estrogens

Wyeth Premarin Petition Withdrawn; Firm Hints At Future Action

Wyeth is reserving its right to file future citizen petitions with regard to the manufacturing of generic Premarin (conjugated estrogens), the company says in a letter formally withdrawing a 1994 petition to block synthetically derived estrogens

Barr Generic Premarin Development Plan Includes Exclusive Supply Deal

Barr anticipates that its exclusive supply agreement with Natural Biologics will permit pricing of its Premarin generic as a single-source generic

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS039075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By